Enliven Therapeutics Announces $165 Million Financing and Advances Two TKIs into Phase I Clinical Trials Following Reverse Merger with Imara

The continued economic downturn in 2022 plunged many industries into a winter chill and adversely impacted all facets of the biotechnology sector. This led to a stagnation in the IPO market, scarce mergers and acquisitions, reduced venture capital investment, and slower new drug approvals, among other effects. According to Evaluate Vantage’s 2022 annual report, total financing in the biotechnology sector amounted to $21.7 billion in 2022, representing an approximately 24% decline from the $28.5 billion raised in 2021.

In particular, due to the inherent constraints of research and development in the biotechnology sector, failure rates appear to be higher than in other industries. Imara Inc., a U.S. biopharmaceutical company that went public in 2020 (NASDAQ: IMRA), had secured approximately $150 million in investment. However, disappointing clinical trial results led the company to shut down its pipeline, sell off its assets, and pursue a reverse merger shell transaction by the end of 2022.

For companies that have yet to secure drug approvals, the level of R&D investment is a key metric for assessing core competitiveness and future growth prospects. According to Imara’s 2022 annual report, the company’s R&D spending plummeted by approximately 50%, from $38.44 million in 2021 to $18.94 million in 2022.

Imara Financial Data

Image source: Imara 2022 Annual Report

In October 2022, Enliven Therapeutics (hereinafter referred to as “Enliven”), a U.S. biopharmaceutical company founded in 2019, announced that it would go public via a reverse merger with Imara. The combined company will operate under the name Enliven Therapeutics and trade on the Nasdaq Global Select Market under the ticker symbol “ELVN.” Following the announcement, Imara’s stock price surged by approximately 40% in the short term.

Enliven Stock Price Trend

Image source: finance.google.com

Despite significant advances in precision oncology, many patients still lack access to specific targeted therapies or have developed resistance to currently available targeted drugs. To address these challenges, Enliven Therapeutics, which focuses on targeted cancer treatments, has established the following three core principles for its drug development:

Guided by validated biological targets for R&D:Enliven leverages the expertise of its R&D team in the field of oncogenic genetic variations, along with its research on existing market products, to select targets.

For example, while several small-molecule kinase inhibitors targeting the BCR-ABL fusion gene are already available on the market, Enliven has identified unmet medical needs—representing potential market opportunities—not addressed by existing products, through its evaluation of this oncogene and related product data. Accordingly, the R&D team has currently defined three strategic entry points:

· Verified oncogenic driver genes with established, effective therapies

· Emerging Oncogenic Driver Genes

· Clinically Validated Signaling Nodes Driving Cancer Cell Proliferation

Differentiated Chemical Composition and Formulation Design:Enliven’s team of chemists has accumulated extensive experience in the design of inhibitors for more than 60 selective kinase targets. Building on this foundation, Enliven has established a unique, ligand-efficient genomic scaffold and integrated multiple technologies to explore development opportunities for selected targets.

Rigorous Clinical Trial Design and Regulatory Strategy:To evaluate the efficacy of drug candidates early in clinical development, Enliven selects cancer patients with multiple biomarkers for its clinical trials, thereby building a high-quality, high-efficiency database.

By leveraging research on targets with established efficacy in third-party clinical trials, Enliven Therapeutics is poised to advance its small-molecule kinase inhibitor pipeline with a higher success rate, drawing on the extensive experience of its R&D team.

Kinases are enzymes that catalyze the transfer of phosphate groups from high-energy donor molecules to specific substrates. Aberrant mutations or expression of protein kinases represent one of the most significant oncogenic drivers and constitute the most extensively studied therapeutic targets in oncology, with approximately 30% of anticancer drug discovery efforts focused on kinase inhibitors.

In 2001, the world’s first tyrosine kinase inhibitor (TKI), imatinib produced by Novartis, received FDA approval, ushering in an era of targeted cancer therapy with small-molecule kinase inhibitors. According to a report published by Spherical Insights & Consulting, the global market size for kinase inhibitors is projected to reach $95.3 billion by 2030.

Facing a future market nearing RMB 100 billion, Enliven currently has two lead development pipelines that have entered Phase I clinical trials.

Lead R&D Pipeline

Image source: Enliven official website

Enliven’s lead pipeline candidate, ELVN-001, primarily targets chronic myeloid leukemia (CML). CML is characterized by the accumulation of immature white blood cells in the bone marrow due to abnormal kinase activation in patients, which suppresses normal hematopoiesis. The initiation and core pathogenesis of most CML cases stem from the BCR-ABL fusion gene. Tyrosine kinase inhibitors (TKIs) can selectively block the binding of ATP to the kinase domain of the BCR-ABL fusion protein, thereby inhibiting signal transduction and inducing apoptosis in BCR-ABL-positive cells.

According to data from the “White Paper on Chinese Patients with Chronic Myeloid Leukemia (2021),” the global annual incidence of CML is 1.6–2.0 per 100,000 people, accounting for approximately 15% of adult leukemia cases. The advent of tyrosine kinase inhibitors (TKIs) has increased the overall 10-year survival rate for patients with chronic myeloid leukemia from 50% to 85%–90%.

Humanity’s battle against chronic myeloid leukemia (CML) has spanned more than half a century. Although the advent of tyrosine kinase inhibitors (TKIs) has significantly improved life expectancy for CML patients, decades of daily therapy have increasingly highlighted challenges related to patient tolerance, safety, drug resistance, and convenience.

Advances in CML Therapy

Image source: Enliven official website

According to data from the Enliven merger agreement, approximately 20% of patients require switch therapy for their tumors within the first year, and approximately 40% switch within five years. Compared with some approved TKIs,Preclinical studies have confirmed that ELVN-001 demonstrates improved kinome selectivity, tolerability, and inhibition of tumor growth.

ELVN-001: Inhibition of Tumor Growth in Preclinical Studies Shows Minimal Time-Dependent Fluctuation

Image source: Enliven official website

T315I is a common mutation in the BCR-ABL kinase domain, conferring resistance to imatinib, nilotinib, dasatinib, and bosutinib.Meanwhile, ELVN-001 demonstrates high activity against T315I., and the use of ELVN-001 does not interfere with the activity and tolerability of other TKIs currently present in patients.ELVN-001 is poised to become a complementary treatment option for CML, primarily targeting second- and third-line therapies.Enliven plans to provide early clinical data for the pipeline by the end of 2023.

ELVN-001: Growth Inhibition of T315I-Mutant Tumors in Preclinical Studies

Image source: Enliven official website

Enliven’s second candidate product, ELVN-002, is a selective, potent, and irreversible HER2 inhibitor that maintains drug activity across various HER2 mutations, including exon 20 insertion mutations (E20IM) in non-small cell lung cancer (NSCLC). According to data from Enliven’s merger agreement, although up to 3% of NSCLC patients harbor E20IM, there are currently no FDA-approved small-molecule drugs specifically targeting this mutation.

ELVN-002: Inhibition of E20IM-mutant tumor growth in preclinical studies shows minimal temporal fluctuation

Image source: Enliven official website

Based on published clinical data from investigational TKIs currently under study, all TKIs targeting the E20M mutation are dual inhibitors of EGFR and HER2; therefore, their dosing is limited by EGFR-related toxicities. In contrast, ELVN-002 is designed to inhibit HER2 and key HER2 mutations while sparing wild-type EGFR and avoiding its associated toxicity.

If Enliven achieves these endpoints in its upcoming clinical trials, then compared with currently approved and investigational TKIs,ELVN-002 is expected to achieve a higher therapeutic index and may provide more valuable treatment options for patients with brain metastases.

According to data from Evaluate Pharma, global sales of the HER2-targeted anti-tumor market are projected to reach $15.6 billion in 2024. Although ELVN-002 initially focuses on HER2 mutations in non-small cell lung cancer (NSCLC), Enliven Therapeutics also plans to expand the drug’s indications to other cancers, such as breast cancer, colorectal cancer, and gastric cancer.

ELVN-002 received FDA IND approval in 2022, and its Phase I clinical trial has been initiated.

In addition to its two pipelines under development, Enliven is also screening and optimizing the chemical compositions of multiple projects, and expects to nominate a candidate product for its third pipeline in the first half of 2023.

Priority Development Plan

Image source: Enliven official website

The three co-founders of Enliven possess extensive and specialized expertise in drug discovery, development, and commercialization.

Co-founder of Enliven Therapeutics

Image source: Enliven official website

Co-founder and CEO Sam Kintz holds a B.S. in Chemistry and an M.B.A. from Stanford University. Sam previously served as a Research Director at AbbVie, worked as a medicinal chemist at Roche Venture Fund, and conducted R&D on small-molecule oncology therapeutics at Genentech.

Another co-founder and CSO, Dr. Joe Lyssikatos, holds a Ph.D. in Chemistry from the University of California, Berkeley, and a B.A. in Chemistry from the College of William & Mary. Joe began his pharmaceutical career at Pfizer’s Groton Laboratories. He has also served as an Executive Director at AbbVie and as a Scientist at Genentech.

Joe has led or supported more than 30 scientific projects and discovered over 15 clinical candidate drugs,The most notable among them include selumetinib (Koselugo), binimetinib (Mektovi), and tucatinib (Tukysa).. Joe is also a co-inventor or co-author of more than 230 patents and peer-reviewed publications.

Dr. Anish Patel, the third co-founder and COO, holds a Pharm.D. from the University of Michigan and a bachelor’s degree in microbiology and chemistry from the University of Illinois. Anish previously served as Head of Medical Affairs at AbbVie Stemcentrx and led the R&D and commercialization of ibrutinib (Imbruvica) at Pharmacyclics, which was later acquired by AbbVie for $21 billion. Anish has also held leadership positions at AstraZeneca and Bayer.

As a chemistry-driven innovator in precision oncology therapies, Enliven’s founding team leverages its mature R&D and commercialization expertise to explore and capitalize on emerging opportunities across additional targets, ultimately developing urgently needed, commercially viable small-molecule kinase inhibitors for patients.

Through a “reverse merger,” Enliven can secure multi-party financing more rapidly in a larger public market.In this acquisition round, Enliven secured approximately $165 million in private equity financing., led by new investors Fairmount and Venrock Healthcare.All of Enliven’s existing investors participated in this oversubscribed financing round., including OrbiMed, 5AM Ventures, Surveyor Capital, Cormorant Asset Management, and Roche Venture Fund.

According to Crunchbase data, Enliven has raised a total of $212 million in funding since its inception. Including the remaining cash from the merger with Imara, Enliven’s current cash reserves have reached $300 million, which is sufficient to sustain the company’s operations until the completion of two clinical trials in 2026.

Enliven Financing History

VCBeat

For innovative pharmaceutical companies without any commercialized products, R&D expenditure is the primary metric used by capital markets to assess their capabilities. According to disclosures in the Enliven merger agreement, Enliven’s R&D spending for the first ten months of 2022 amounted to $23.8253 million.Compared with the R&D investment of $13.61 million in the first 10 months of 2021, it increased by approximately 75%, while compared with the full-year figure of $8.24 million in 2020, it surged by approximately 180% in just the first 10 months of 2022.

Enliven Financial Data

Source: Enliven Merger Agreement

Although Enliven’s net loss has been gradually increasing, the net loss per share decreased from $3.80 in 2020 to $2.70 in 2022, driven by equity dilution following its public listing and subsequent financing. This demonstrates that Enliven, as an innovative biopharmaceutical company with drug candidates still in the clinical stage, has already gained recognition from the market and investors.

In March this year, the TD Cowen division of a Canadian investment bank assigned an “Outperform” rating to Enliven’s stock performance, and further predicted that the value of Enliven’s drugs would exceed $100 billion by 2025.